Infinity Pharmaceuticals Inc.
780 Memorial Drive
Cambridge
Massachusetts
02139
United States
Tel: 617-453-1000
Fax: 617-453-1001
Website: http://www.infi.com/
Email: info@infi.com
About Infinity Pharmaceuticals Inc.
The mission of Infinity Pharmaceuticals, Inc. is to discover, develop, and deliver to patients best-in-class medicines for the treatment of difficult-to-treat diseases, with a strong focus in oncology and inflammation.Small molecule discovery and development capabilities Infinity’s programs arise from the integration of a broad range of research and development capabilities, including strengths in cancer biology, medicinal chemistry, clinical and translational medicine, and drug product process development and formulation.
Strategic alliances Building on its strengths in innovative small molecule drug discovery and development, Infinity has established significant alliances with leading pharmaceutical and biotechnology companies to help realize the full potential of its product pipeline.
Business and scientific expertise The company has assembled a team of passionate, committed, and innovative individuals who bring together their collective expertise in all areas of business and drug discovery and development.
Culture of Citizen-Ownership Infinity’s culture and environment of Citizen-Ownership is as important as its technologies. Infinity works together as a community with the shared goal of bringing important new medicines to patients.
466 articles about Infinity Pharmaceuticals Inc.
-
Infinity Pharmaceuticals, Inc. Names Adelene Q. Perkins Chief Executive Officer
12/7/2009
-
Infinity Pharmaceuticals, Inc.'s IPI-504 Named One of Windhover Information Inc. and Campbell Alliance's "Top 10 Projects to Watch" in Oncology
11/17/2009
-
Infinity Pharmaceuticals, Inc. to Present at Upcoming Conferences
11/10/2009
-
Infinity Pharmaceuticals, Inc. Announces Third Quarter 2009 Results Conference Call
11/2/2009
-
Infinity Pharmaceuticals, Inc. Announces Appointment of Dr. Thomas J. Lynch to Its Board of Directors
10/7/2009
-
Infinity Pharmaceuticals, Inc. to Present At Upcoming Conferences
9/2/2009
-
Infinity Pharmaceuticals, Inc. Reports Recent R&D Highlights and Second Quarter 2009 Results
8/6/2009
-
Infinity Pharmaceuticals, Inc. Added to Russell 2000(r) Index
6/29/2009
-
Infinity Pharmaceuticals, Inc. Reports Encouraging Clinical Data for IPI-504 at American Society of Clinical Oncology 2009
6/1/2009
-
New Paper in Science Features Infinity Pharmaceuticals, Inc.'s IPI-926 Hedgehog Pathway Inhibitor as a Promising New Approach in Chemo-Resistant Pancreatic Cancer
5/29/2009
-
Infinity Pharmaceuticals, Inc. Named Winner of The Scientist's 'Best Places to Work in Industry' and Featured in Boston Business Journal's Best Places to Work 2009 Survey
5/27/2009
-
Clinical Data From Infinity Pharmaceuticals, Inc.'s Hsp90 Chaperone Inhibitor Program to be Presented During American Society of Clinical Oncology Meeting
5/13/2009
-
Infinity Pharmaceuticals, Inc. Reports Recent Pipeline Developments and First Quarter 2009 Results
5/5/2009
-
Infinity Pharmaceuticals, Inc. Halts Phase III RING Trial in Advanced Gastrointestinal Stromal Tumors
4/15/2009
-
Infinity Pharmaceuticals, Inc. to Present Preclinical Data From Its Hsp90 Inhibitor Program and Its Hedgehog Signaling Pathway Inhibitor Program At American Association for Cancer Research Meeting
4/8/2009
-
Infinity Pharmaceuticals, Inc. Announces Leadership Promotions
4/7/2009
-
Infinity Pharmaceuticals, Inc. Presents the Chemistry and Discovery of IPI-926, Its Novel Hedgehog Signaling Pathway Inhibitor, At American Chemical Society Meeting
3/25/2009
-
Infinity Pharmaceuticals, Inc. to Present the Discovery of IPI-926, Its Hedgehog Signaling Pathway Inhibitor, At American Chemical Society Meeting
3/17/2009
-
Infinity Pharmaceuticals, Inc. to Present At Upcoming Conferences
3/3/2009
-
Infinity Pharmaceuticals, Inc. Well-Financed to Achieve 'I4 2012' Long-Term Goals; Announces 2008 Financial Results
2/10/2009